Last Updated: 30/04/2024
Phase Ib age de-escalation and dose escalation of Pfs25-IMX313/Matrix-M intramuscularly in healthy adults and young children in Tanzania
Objectives
This study aims to evaluate safety, immunogenicity, and transmission blocking activity of Pfs25IMX313-Matrix-M in healthy Tanzanian adults and children naturally exposed to malaria in Bagamoyo district, Tanzania.
A phase Ib age de-escalation and dose escalation open label clinical trial of the safety, immunogenicity and ex-vivo efficacy of a candidate malaria vaccine Pfs25-IMX313/Matrix-M administered intramuscularly in healthy adults and young children in Tanzania
Study type: Interventional
Enrollment: 52 participants
Primary purpose: Treatment
Allocation :Non- Randomized
Interventional Model : Parallel Assignment
Masking : Open label
NCT number: NCT04271306
Phase: Phase Ib
May 2021 — Mar 2023
Related Resources
No related items found
